NCT06711705

Elranatamab in Relapsed/Refractory Multiple Myeloma

Phase II MRD-Adapted Study of Elranatamab in Relapsed/Refractory

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: University of California, San Diego · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.

Detailed description

Phase II study of elranatamab in patients with relapsed/refractory multiple myeloma who has received 1 to 3 prior lines of therapy. Patients may enter treatment-free observation period if they have a sustained MRD negative response for greater than 12 months.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Elranatamab	Subcutaneous injection of elranatamab. If patient achieves MRD negative remission, patient would enter treatment-free observation period with MRD monitoring.

Timeline

• Start date: 2024-12-18
• Primary completion: 2029-12-01
• Completion: 2030-12-01
• First posted: 2024-12-02
• Last updated: 2026-02-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study